Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
08 janv. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif. and MONTREAL, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing state-of-the-art...
Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares
14 déc. 2018 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its...
Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock
12 déc. 2018 01h01 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an...
Fluidigm Announces Commencement of Public Offering of Common Stock
11 déc. 2018 16h01 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to...
Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
12 nov. 2018 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s...
Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018
08 nov. 2018 08h30 HE
|
Fluidigm Corporation
A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation...
Fluidigm Recognized as a Company to Watch in 2019
07 nov. 2018 16h11 HE
|
Fluidigm Corporation
Immuno-oncology innovator receives life science people’s choice award SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm...
Fluidigm Announces Third Quarter 2018 Financial Results
01 nov. 2018 16h05 HE
|
Fluidigm Corporation
Total revenue increases 17 percent to $29.0 million Mass cytometry revenue growth of 50 percent Instrument revenue growth of 32 percent SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018...
Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System
25 oct. 2018 08h30 HE
|
Fluidigm Corporation
Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) --...
Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
01 oct. 2018 16h15 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report...